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ABSTRACT 
INTRODUCTION:  Bisphosphonates are effective for treating osteoporosis, Paget's 
disease of bone, and malignancy-associated bone diseases. Bisphosphonate-associated 
osteonecrosis of the jaw (ONJ) is a rare but serious adverse ffect of bisphosphonate 
therapy. Due to inhibitory actions on bone turnover, bisphosphonate herapy may 
result in the accumulation of microdamage. 
CASE SUMMARY:  A 74-year-old Korean woman (height, 150 cm; weight, 
51 kg) was referred to the Department of Endocrinology and Metabolism, Ajou Uni- 
versity School of Medicine, Suwon, South Korea, for evaluation of pain and persistent 
abnormal exposure of jaw bone after extraction of teeth. She had been receiving 
weekly oral alendronate treatment for osteoporosis for -5 years. The patient had the 
clinical features of bisphosphonate-associated osteonecrosis of the mandible, which 
was precipitated by teeth extraction - 14 months prior to the outpatient referral visit. 
At her clinical baseline visit, serum hormone concentrations and bone turnover mark- 
ers were as follows: thyroid-stimulating hormone, 0.88 lalU/mL (reference range, 
0.25 5.00 lalU/mL); 25-hydroxyvitamin D3, 20.9 (9.0 37.6) ng/mL; parathyroid hor- 
mone (PTH), 57 (11 62) pg/mL; serum osteocalcin, 8.7 (12.9 55.9) ng/mL; and urine 
N-telopeptide 21 (26 124) nM/mM creatinine. She had multiple systemic risk factors 
for ONJ, including older age, type 2 diabetes mellitus, and long duration of bisphos- 
phonate therapy. There was no mandibular lesion improvement despite repeated sur- 
gical procedures performed within a 14-month period. Bisphosphonate herapy was 
discontinued and PTH therapy was started. After 2 months, exposed oral mucosa had 
healed. After 4 months of treatment, he pain had completely subsided, and after 
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6 months the patient's eating and drinking habits returned. The serum concentration f
osteocalcin, a bone formation marker, which was initially suppressed (8.7 ng/mL), 
increased 174% (15.1 ng/mL) from baseline after 6 months of treatment with 
PTH. 
CONCLUSIONS:  Here we report a probable case of oral bisphosphonate-associated 
ONJ featuring suppressed bone turnover. Treatment with the bone formation- 
stimulating agent PTH was beneficial. (Cuff Thef Res Cli~l Exp. 2008;69:356 362) © 
2008 Excerpta Medica Inc. 
KEY WORDS:  osteonecrosis of the jaw, bisphosphonate, alendronate, osteoporosis, 
parathyroid hormone treatment. 
INTRODUCTION 
Bisphosphonate-associated osteonecrosis of the jaw (ONJ) is a rare but serious adverse 
effect of bisphosphonate herapy that is characterized by poor wound healing and 
spontaneous intra-oral soft-tissue breakdown, leading to exposure of necrotic maxil- 
lary or mandibular bone. 1 Due to its inhibitory action on bone turnover, bisphospho- 
nate therapy may result in accumulated microdamage and ONJ. 2,3 
Since it was first described in 2003, an increasing number of ONJ case reports 
has created worldwide attention on the nature, prevention, and treatment of the 
disease.4 6ONJ has been related to the use of potent nitrogen-containing bisphos- 
phonates, such as zoledronate, pamidronate, alendronate, and risedronate, with the 
vast majority of cases reported in patients with cancer who use parenteral bisphos- 
phonates. 6 However, the increasing incidence of ONJ in patients with osteoporo- 
sis 7'8 has caused experts to caution against the potential risks of prolonged use of 
bisphosphonates. 
We report the case of a 74-year-old Korean woman with a probable case of 
bisphosphonate-associated ONJ. After -6  months of parathyroid hormone (PTH) 
treatment, he ONJ resolved. 
CASE REPORT 
A 74-year-old Korean woman (height, 150 cm; weight, 51 kg) was referred to the 
Department of Endocrinology and Metabolism, Ajou University School of Medicine, 
Suwon, South Korea, for evaluation of pain and persistent abnormal exposure of jaw 
bone after extraction of teeth. The left mandibular first and second molars were 
extracted - 14 months earlier; however, the wound did not heal. Short-term treatment 
with amoxicillin (500 mg TID) in 3 treatment periods (consisting of 4 days each dur- 
ing the months of May, June, and July in the same year) had been administered but 
without improvement. Debridement and curettage were performed 5 times without 
success. Subsequently, the patient was referred to the Endocrinology Clinic. The 
patient's medical history revealed hypertension, type 2 diabetes mellitus, and osteo- 
porosis. She was being treated with glimepiride 2 mg for diabetes mellitus, valsartan 
160 mg and hydrochlorothiazide 12.5 mg for hypertension, and calcium citrate 1500 mg 
and vitamin D 800 IU daily for osteoporosis. In addition, the patient had been receiv- 
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ing alendronate* 70 mg weekly for -5 years. Plain radiograph study taken in October 
2001 revealed multiple compression fractures of thoracic and lumbar vertebrae (TS, 
T8, T9, T 10, T 12, L 1, and L2). Her initial (2001) bone mineral density (BMD) of the 
femoral neck, determined using dual-energy x-ray absorptiometry (Hologic Inc., 
Bedford, Massachusetts), was 0.482 g/cm 2 with a T-score of 3.0 and the total femur 
was 0.526 g/cm 2 with a T-score of 2.8. The patient had no history of malignancy or 
radiation therapy. 
On examination, the patient's vitals were: blood pressure, 131/69 mm Hg; pulse 
rate, 85 beats/min; and body temperature, 36.7°C. Although the patient appeared to 
be chronically ill, she was mentally alert and neurologic examination was unremark- 
able. There was no evidence of blue sclerae; however, spinal kyphosis was detected. 
Chest and abdominal examinations were normal (clear breathing sounds heard via 
stethoscope and no abdominal tenderness on palpation). Examination of the oral cavi- 
ty revealed exposed left mandible bone in the first and second molar area without 
intra- or extraoral sinus track. There was no intraoral mass or abscess. There were no 
palpable submandibular o cervical ymph nodes detected. 
Laboratory findings were as follows: serum calcium, 9.3 mg/dL; serum phosphate, 
3.2 mg/dL; blood glucose, 126 mg/dL (normal reference range, 70 110 mg/dL); hemo- 
globin Ale, 6.3% (4.3% 6.1%); blood urea nitrogen, 18.9 (8.0 25.0) mg/dL; serum 
creatinine (Cr), 1.0 (0.5 1.4) mg/dL; serum ionized calcium, 4.4 (4.2 5.4) mg/dL; total 
alkaline phosphatase, 78 (20 120) U/L; serum total protein, 7.1 (6.0 8.5) g/dL; serum 
albumin, 4.2 (3.5 5.3) g/dL; aspartate aminotransferase, 29 (5/40) U/L; alanine ami- 
notransferase, 20 (8 31) U/L; serum total cholesterol, 142 (120 220) mg/dL; serum 
triglyceride, 130 (35 180) mg/dL; serum high-density lipoprotein cholesterol, 53 (40 
100) mg/dL; and serum C-reactive protein, 0.72 (0.02 0.80) mg/dL. The serum hor- 
mone concentrations and bone turnover markers were as follows: thyroid-stimulating hor- 
mone, 0.88 lalU/mL (normal reference range, 0.25 5.00 lalU/mL); 25-hydroxyvitamin D3, 
20.9 (9.0 37.6) ng/mL; PTH, 57 (11 62) pg/mL; serum osteocalcin, 8.7 (12.9 
55.9) ng/mL; and urine N-telopeptide, 21 (26 124) nM/mM Cr. 
According to the patient's medical reports, when compared with a previous (2001) 
radiograph, an April 2007 radiograph showed that the spinal fractures appeared un- 
changed but a new fragility fracture had developed at the left elbow. A panoramic 
radiograph taken in March 2007 revealed osseous clerosis of alveolar bone with un- 
healed extraction sockets. A bone biopsy was performed in April 2007 and revealed 
osteonecrosis, showing dead bone with empty lacunae and bony resorption. A follow- 
up BMD study (June 2007) revealed results similar to those of a 2001 BMD study: 
the femoral neck was 0.434 g/cm 2 with a T-score of 3.5 and the total femur was 
0.549 g/cm 2 with a T-score of 2.6. 
Based on the combined observations and clinical findings, the diagnosis of ONJ 
was made and alendronate was discontinued. The oral calcium and vitamin D, the 
hypoglycemic drug, and the antihypertensive drugs were continued. Conservative 
management with oral antibiotics (amoxicillin plus clavulanate [625 mg TID]) was 
*Trademark: Fosamax ® (Merck & Co. Inc., Whitehouse Station, New Jersey). 
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started. In this context of suppressed bone turnover associated with ONJ, treatment 
with a bone formation stimulating agent would probably be beneficial. Treatment with 
the recombinant human PTH teriparatide*, 20 lag/d SQ, was initiated 2 days later. 
The biochemical markers of bone turnover monitored during PTH treatment 
showed a marked increase in serum osteocalcin concentration without significant 
change in urine N-telopeptide (Table). After 2 months of PTH treatment, he ex- 
posed oral mucosa had resolved. After 4 months, the pain had completely subsided, 
and after 6 months, the patient's eating and drinking habits returned to normal. 
DISCUSSION 
Bisphosphonates are effective for treating osteoporosis, Paget's disease of bone, and 
malignancy-associated bone diseases. Bisphosphonates are prescribed widely in differ- 
ent doses and potencies and for different durations. 
Since first described in 2003, increasing numbers of ONJ case reports have caused 
experts to caution against he potential risks of prolonged use of bisphosphonates. The 
American Association of Oral and Maxillofacial Surgeons (AAOMS) published a 
bisphosphonate-related ONJ position paper, 9and the American Society for Bone and 
Mineral Research (ASBMR) 1°reported results of a bisphosphonate-associated ONJ 
task force study. Epidemiologic data regarding disease prevalence are currently limit- 
ed to retrospective studies with limited sample size. The estimated cumulative inci- 
dence of ONJ from IV bisphosphonate therapy ranges from 0.8% to 12%. 9 Patients 
treated with oral bisphosphonates are at lower risk for ONJ than patients receiving IV 
bisphosphonates. The ASBMR task force reported an estimated risk of between < 1 in 
10,000 to 1 in 100,000 patient-treatment years. 1° 
According to the working definition of the AAOMS and ASBMR, 9,1° patients with 
all 3 of the following characteristics are considered to have bisphosphonate-associated 
ONJ: (1) current or previous treatment with a bisphosphonate; (2) exposed, necrotic 
bone in the maxillofacial region that has persisted for >8 weeks; and (3) no history of 
radiation therapy to the jaw. The suggested risk factors for developing ONJ are clas- 
sified as drug-related, local, demographic, and systemic. 9 Local risk factors may in- 
clude recent dentoalveolar surgery, such as extractions, placement of dental implants, 
periapical surgery, and periodontal surgery involving osseous injury. Other local fac- 
tors include local anatomy, such as lingual or palatal tori, sharp mylohyoid ridges, and 
concomitant oral diseases, such as periodontal or dental abscesses. 1,9 Demographic and 
systemic factors include increasing age, cancer, osteopenia or osteoporosis, corticoster- 
oid therapy, diabetes, smoking, alcohol use, poor oral hygiene, and chemotherapeutic 
drugs. 1,9 
The patient in the current report met all 3 diagnostic criteria for bisphosphonate- 
associated ONJ according to the AAOMS and the ASBMR. Her oral mucosal esion/ 
ulceration and mandibular bone exposure were precipitated by molar extraction and 
later aggravated by repeated ebridement and curettage. During the 14 months prior 
to bisphosphonate-associated ONJ diagnosis, there had been no oral lesion improve- 
*Trademark: Forteo ® (Eli Lilly and Company, Indianapolis, Indiana). 
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ment in spite of frequent local dental procedures. However, after bisphosphonate was 
discontinued and was replaced with PTH treatment, clinical improvement was noted. 
In addition, the patient had multiple systemic risk factors, including old age, type 2 
diabetes mellitus, and continuous bisphosphonate herapy for -5  years. Her Naranjo 
adverse drug reaction scale 11 score of 5 indicated a probable relationship between 
alendronate treatment and ONJ. 
No effective therapy for bisphosphonate-associated ONJ  has been established, and 
empirical conservative therapy is recommended in the guidelines of both the AAOMS 
and the ASBMR. Extensive debridement and local flap closure seem to be unsuccess- 
ful. Removal of only symptomatic bony sequestra with minimal disturbance of over- 
lying soft tissue, along with topical and systemic antibiotics, may be appropriate. 1 
Harper and Fung 12 reported that PTH treatment improved healing of soft tissue 
and necrotic bone in a case of oral bisphosphonate-associated ONJ. In their case, they 
treated the patient with PTH 20 lag/d SQ. After 3 months of treatment, significant 
reductions in the size and number of ulcerations of the mandibular mucosa were re- 
ported. After 10 months of treatment with PTH, the mucosa was completely healed. 
The anabolic bone response to discontinuation of bisphosphonate reatment and ini- 
tiation of PTH is expected to take 6 months to 1 year.13,14 However, response can occur 
within 2 months of PTH treatment.15 In this case, clinical signs of soft-tissue healing of 
the oral cavity lesion were apparent after 2 months of treatment with PTH. 
We measured the biochemical bone markers in this case as surrogate indicators of 
the bone changes associated with PTH treatment. After 6 months of treatment, he 
serum concentration of the bone formation marker osteocalcin increased -2  times 
compared with baseline. In contrast, the urine concentration of the bone resorption 
marker N-telopeptide was unchanged, most likely due to severely suppressed osteo- 
clastic activity. Early responses in formation markers and delayed catch-up in resorp- 
tion markers are typical characteristics of PTH treatment. 
CONCLUSION 
In this probable case of oral bisphosphonate-associated ONJ featuring suppressed bone 
turnover, treatment with the bone formation-stimulating agent PTH was beneficial. 
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